Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed’s Chief Legal Officer Michael Alexander Smith received new equity awards. On January 2, 2026, he was granted 5,293 Restricted Stock Units (RSUs), each equal to one share of common stock, under Insmed’s Amended and Restated 2019 Incentive Plan. The RSUs vest 25% on the first day of the first month following the first anniversary of the grant date, then 25% on each anniversary of that initial vesting date until fully vested. The grant increased his directly held common stock to 60,195 shares.
On the same date, he was also granted 27,600 stock options with an exercise price of $177.12 per share, expiring on January 2, 2036. These options vest 25% on the initial vesting date, with an additional 12.5% every six months thereafter until fully exercisable. Following this grant, he holds 27,600 stock options directly.
Insmed Incorporated reported topline results from its Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) and announced that it has discontinued development of brensocatib for this indication. The 24‑week, randomized, double‑blind, placebo‑controlled study enrolled 288 patients across 104 global sites, comparing once‑daily brensocatib 10 mg, brensocatib 40 mg, and placebo, all on top of mometasone furoate nasal spray.
The primary endpoint was change from baseline in the 28‑day average daily Sinus Total Symptom Score at Week 24. Least squares mean changes were -2.44 for placebo, -2.21 for brensocatib 10 mg, and -2.33 for brensocatib 40 mg. Brensocatib was observed to be well tolerated, with similar rates of treatment‑emergent and serious adverse events across arms. Insmed also disclosed it has acquired INS1148, an investigational monoclonal antibody it plans to develop for respiratory, immunological, and inflammatory diseases with high unmet need.
Insmed Inc. (INSM) reported an insider transaction on a Form 4 filing. A company director sold 5,000 shares of Insmed common stock on November 24, 2025, identified with transaction code "S" for a sale. The shares were sold at a price of $204.58 per share in an open market transaction.
After this sale, the director beneficially owns 58,729 shares of Insmed common stock, held directly. The filing reflects a routine update to the director’s ownership position and does not report any derivative securities activity.
Insmed Inc director Leo Lee reported multiple sales of Insmed Common Stock on November 17, 2025, totaling 75,000 shares. Footnotes describe weighted average sale prices ranging from $193.00 to $197.78 per share. After these trades, Lee directly held 54,677 Insmed common shares.
Insmed Inc. (INSM) reported an insider stock sale by a company director. On 11/14/2025, the director sold 10,000 shares of common stock at a price of $195.87 per share, according to a Form 4 filing. After this transaction, the director continues to hold 63,729 shares directly. This filing simply records a change in the director’s personal holdings and does not, by itself, change the company’s operations or financial results.
Insmed Incorporated announced that the European Commission has approved its drug BRINSUPRI (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis in certain younger and adult patients. The approval covers patients 12 years of age and older who have experienced two or more exacerbations in the prior 12 months, addressing a population with recurrent respiratory flare-ups. Insmed disclosed the news in connection with a press release, which is included as an exhibit to the report.
Insmed (INSM) reported an insider transaction by its Chief People Strategy Officer on 11/12/2025. The officer exercised 30,000 stock options at an exercise price of $26.46 and received common shares. On the same day, the officer sold shares in four tranches at weighted average prices of $192.45 (4,078 shares), $193.64 (6,575), $194.44 (19,183), and $195.88 (164), with ranges disclosed for each tranche. Following these transactions, the officer directly owned 36,461 common shares. Remaining derivative holdings were 15,760 options expiring on 05/12/2031, which are currently exercisable as described.
Insmed Inc. (INSM) reported insider transactions by its Chief Medical Officer on 11/11/2025. The officer exercised stock options for 12,949 shares at $17.07 and 18,277 shares at $18.95 (transaction code M), then sold shares in open-market trades (transaction code S) under a Rule 10b5-1 plan adopted on February 27, 2025.
Sales were executed at weighted average prices of $188.38 for 5,467 shares (range $187.93–$188.90), $189.36 for 12,224 shares (range $188.90–$189.88), $190.33 for 10,622 shares (range $189.92–$190.90), and $191.04 for 2,913 shares (range $190.94–$191.14). Following these transactions, the officer reported 83,111 shares beneficially owned directly. The disclosed options carry expirations on 05/11/2032 and 05/11/2033, with vesting at 25% on the first anniversary and 12.5% each six months through the fourth anniversary.
Insmed (INSM) filed a Form 4 disclosing a gift transfer by a director. On 11/06/2025, the reporting person executed a Code G transaction, gifting 60,000 shares of common stock at $0.
Following the transaction, the director held 66,933 shares directly and 60,000 shares indirectly, listed as held by spouse revocable trust. The filing indicates a change in the form of ownership, not an open-market trade.
Insmed (INSM) reported an insider transaction by its Chief Legal Officer. On 11/03/2025, the officer exercised 27,130 stock options at an exercise price of $23.75 and sold shares in multiple tranches under a Rule 10b5-1 trading plan adopted on February 27, 2025.
The sales were executed at weighted average prices ranging from $181.01 to $187.97, with the filing noting price ranges and an undertaking to provide per-price breakdowns upon request. Following the reported transactions, the officer beneficially owned 54,902 shares directly.